221 related articles for article (PubMed ID: 29318656)
1. Circadian genes and risk of prostate cancer in the prostate cancer prevention trial.
Chu LW; Till C; Yang B; Tangen CM; Goodman PJ; Yu K; Zhu Y; Han S; Hoque AM; Ambrosone C; Thompson I; Leach R; Hsing AW
Mol Carcinog; 2018 Mar; 57(3):462-466. PubMed ID: 29318656
[TBL] [Abstract][Full Text] [Related]
2. The influence of finasteride on the development of prostate cancer.
Thompson IM; Goodman PJ; Tangen CM; Lucia MS; Miller GJ; Ford LG; Lieber MM; Cespedes RD; Atkins JN; Lippman SM; Carlin SM; Ryan A; Szczepanek CM; Crowley JJ; Coltman CA
N Engl J Med; 2003 Jul; 349(3):215-24. PubMed ID: 12824459
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival of participants in the prostate cancer prevention trial.
Thompson IM; Goodman PJ; Tangen CM; Parnes HL; Minasian LM; Godley PA; Lucia MS; Ford LG
N Engl J Med; 2013 Aug; 369(7):603-10. PubMed ID: 23944298
[TBL] [Abstract][Full Text] [Related]
4. Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia.
Gu F; Zhang H; Hyland PL; Berndt S; Gapstur SM; Wheeler W; Ellipse Consortium T; Amos CI; Bezieau S; Bickeböller H; Brenner H; Brennan P; Chang-Claude J; Conti DV; Doherty JA; Gruber SB; Harrison TA; Hayes RB; Hoffmeister M; Houlston RS; Hung RJ; Jenkins MA; Kraft P; Lawrenson K; McKay J; Markt S; Mucci L; Phelan CM; Qu C; Risch A; Rossing MA; Wichmann HE; Shi J; Schernhammer E; Yu K; Landi MT; Caporaso NE
Int J Cancer; 2017 Nov; 141(9):1794-1802. PubMed ID: 28699174
[TBL] [Abstract][Full Text] [Related]
5. Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
Neuhouser ML; Till C; Kristal A; Goodman P; Hoque A; Platz EA; Hsing AW; Albanes D; Parnes HL; Pollak M
Cancer Prev Res (Phila); 2010 Mar; 3(3):279-89. PubMed ID: 20179296
[TBL] [Abstract][Full Text] [Related]
6. High-grade prostate cancer and finasteride.
Lebdai S; Bigot P; Azzouzi AR
BJU Int; 2010 Feb; 105(4):456-9. PubMed ID: 19930174
[TBL] [Abstract][Full Text] [Related]
7. [The Prostate Cancer Prevention Trial (PCPT). Relevance for clinical practice].
Schmitz-Dräger BJ; Fischer C; Bismarck E; Dörsam HJ; Lümmen G
Urologe A; 2007 Oct; 46(10):1364, 1366-8, 1370. PubMed ID: 17874228
[TBL] [Abstract][Full Text] [Related]
8. Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study.
Yao S; Till C; Kristal AR; Goodman PJ; Hsing AW; Tangen CM; Platz EA; Stanczyk FZ; Reichardt JK; Tang L; Neuhouser ML; Santella RM; Figg WD; Price DK; Parnes HL; Lippman SM; Thompson IM; Ambrosone CB; Hoque A
Cancer Causes Control; 2011 Aug; 22(8):1121-31. PubMed ID: 21667068
[TBL] [Abstract][Full Text] [Related]
9. Associations of serum sex steroid hormone and 5α-androstane-3α,17β-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride.
Kristal AR; Till C; Tangen CM; Goodman PJ; Neuhouser ML; Stanczyk FZ; Chu LW; Patel SK; Thompson IM; Reichardt JK; Hoque A; Platz EA; Figg WD; Van Bokhoven A; Lippman SM; Hsing AW
Cancer Epidemiol Biomarkers Prev; 2012 Oct; 21(10):1823-32. PubMed ID: 22879203
[TBL] [Abstract][Full Text] [Related]
10. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
Cohen YC; Liu KS; Heyden NL; Carides AD; Anderson KM; Daifotis AG; Gann PH
J Natl Cancer Inst; 2007 Sep; 99(18):1366-74. PubMed ID: 17848668
[TBL] [Abstract][Full Text] [Related]
11. Effect of finasteride on risk of prostate cancer: how little we really know.
Rubin MA; Kantoff PW
J Cell Biochem; 2004 Feb; 91(3):478-82. PubMed ID: 14755678
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial.
Neuhouser ML; Platz EA; Till C; Tangen CM; Goodman PJ; Kristal A; Parnes HL; Tao Y; Figg WD; Lucia MS; Hoque A; Hsing AW; Thompson IM; Pollak M
Cancer Prev Res (Phila); 2013 Feb; 6(2):91-9. PubMed ID: 23315596
[TBL] [Abstract][Full Text] [Related]
13. Correlation between circadian gene variants and serum levels of sex steroids and insulin-like growth factor-I.
Chu LW; Zhu Y; Yu K; Zheng T; Chokkalingam AP; Stanczyk FZ; Gao YT; Hsing AW
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3268-73. PubMed ID: 18990770
[TBL] [Abstract][Full Text] [Related]
14. Serum lycopene concentration and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
Kristal AR; Till C; Platz EA; Song X; King IB; Neuhouser ML; Ambrosone CB; Thompson IM
Cancer Epidemiol Biomarkers Prev; 2011 Apr; 20(4):638-46. PubMed ID: 21335507
[TBL] [Abstract][Full Text] [Related]
15. Finasteride decreases the risk of prostatic intraepithelial neoplasia.
Thompson IM; Lucia MS; Redman MW; Darke A; La Rosa FG; Parnes HL; Lippman SM; Coltman CA
J Urol; 2007 Jul; 178(1):107-9; discussion 110. PubMed ID: 17499284
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction?
Lynn R; Krunic A
Dermatol Ther; 2010; 23(5):544-6. PubMed ID: 20868409
[TBL] [Abstract][Full Text] [Related]
17. Five-alpha-reductase Inhibitors for prostate cancer prevention.
Wilt TJ; MacDonald R; Hagerty K; Schellhammer P; Kramer BS
Cochrane Database Syst Rev; 2008 Apr; (2):CD007091. PubMed ID: 18425978
[TBL] [Abstract][Full Text] [Related]
18. [The PCPT trial].
Hamdy FC; Rouprêt M
Prog Urol; 2008 Apr; 18 Suppl 3():S40-3. PubMed ID: 18455082
[TBL] [Abstract][Full Text] [Related]
19. The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.
Reed AB; Parekh DJ
Curr Opin Urol; 2009 May; 19(3):238-42. PubMed ID: 19318950
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide vs. placebo in men with prostate cancer. Efficacy monitored by karyometry.
Montironi R; Bartels PH; DeCensi A; Puntoni M; Hurle R; Decobelli O; Carmignani G; Mazzucchelli R; Bartels HG; Alberts DS; Maffezzini M
Urol Oncol; 2013 Jul; 31(5):557-65. PubMed ID: 21783387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
